Bausch Health Companies Inc

Bausch Health shares jumped 28.85 percent on Thursday to close at $6.03 after the company reported a strong second quarter that swung to a net income of $260 million, a 103 percent increase from the same period last year. Revenues rose 12.7 percent to $2.852 billion, driven by product sales, with the Salix business segment remaining the largest revenue generator and posting 21 percent growth. The company raised its full-year revenue outlook to a range of $10.79 billion to $11.04 billion, up from prior guidance of $10.67 billion to $10.92 billion, and lifted its adjusted EBITDA target to $4.05 billion to $4.175 billion. Despite the improved performance, institutional participation declined in the first quarter, with 31 hedge funds holding positions compared to 34 in the prior quarter, and combined holdings falling 24.4 percent to $732.9 million.

Glucotrack, Bausch Health, and Corcept Therapeutics were among Thursday's top biotech gainers, driven by pipeline progress and strong financial results. Glucotrack's subsidiary Lokahi Therapeutics advanced development of LT-100, a non-narcotic therapy derived from honeybee venom, with plans to begin clinical evaluation of a simplified single-injection method as early as the fourth quarter of 2026, sending shares up 173.68% to $0.78. Bausch Health raised its full-year 2026 revenue outlook to between $10.790 billion and $11.040 billion after reporting second-quarter consolidated revenue of $2.85 billion, a 13% increase, and its stock rose 28.85% to $6.03. Corcept Therapeutics posted second-quarter net income of $43.0 million on revenue of $256.1 million, including $208.6 million from Korlym and its authorized generic and $47.6 million from newly launched Lifyorli, and lifted its 2026 revenue forecast to $1.1 billion to $1.2 billion, pushing shares up 27.29% to $118.32. Nuwellis surged 135.45% to $4.45 after a study on its Aquadex therapy was accepted by a peer-reviewed journal, while Neogen touched a 52-week high of $11.56 and closed up 22.26% at $11.53 following its fiscal 2026 results and fiscal 2027 guidance.

Bausch Health Companies reported second-quarter 2026 adjusted earnings of $1.26 per share, beating the Zacks Consensus Estimate of 96 cents and rising 40% year over year. Revenues increased 13% to $2.85 billion, surpassing the consensus of $2.65 billion, driven by growth in Salix, Solta Medical, and Bausch + Lomb. Salix revenues climbed 21% to $758 million, with Xifaxan up 26% to $664 million, while Solta Medical surged 38% to $176 million. The company raised its full-year 2026 consolidated revenue guidance to a range of $10.79 billion to $11.04 billion, up from the prior $10.67 billion to $10.92 billion, and lifted its adjusted EBITDA forecast to between $4.05 billion and $4.18 billion.

Bausch Health Canada, a subsidiary of Bausch Health Companies, has listed the 75mg and 100mg dosages of PrOKEDI in the Régie de l'assurance maladie du Québec formulary. PrOKEDI is an injectable risperidone suspension for adults with schizophrenia that achieves therapeutic levels within hours without oral supplementation and provides sustained release over four weeks. The company called the listing a major milestone toward reimbursement in Quebec and said it will continue pursuing coverage in other provinces. This follows a June 9 announcement that Bausch Health Canada completed negotiations with the pan-Canadian Pharmaceutical Alliance, resulting in a Letter of Intent for both dosages.